Therapeutic use of a thienylcyclohexylamine derivative
US6784194B2 · kind B2 · utility
1Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2001 |
| Grant date | Aug 31, 2004 |
| Priority date | — |
| Expiry date | Apr 23, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4535
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of inhibiting effects of exogenous neurotoxic or neurotoxinic products in warm-blooded animals comprising administering to warm-blooded animals before exposure to said products an inhibitorily effective amount of reversible cholinesterase inhibitor selected from the group consisting of pyridostigmine and physostigmine followed by administration of an inhibitorily effective amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.